MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1692287

Медицинская библиотека · Frontiers in immunology · 2026

CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch.

Huang Jiawen, Huang Xiaobing, Yu Duonan

СтатьяОбзорПеревод в очереди

Аннотация

CD19 chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of relapsed/refractory B-cell malignancies, achieving high remission rates. Nonetheless, 20%-40% of patients eventually relapse, classified as either CD19+ or CD19- relapse. Most relapses are CD19+, largely due to reduced potency and poor persistence of CAR-T cells after infusion. In contrast, a substantial fraction of patients develops CD19- relapse driven by selective pressure from CAR-T cell therapy. Post-CAR-T cell CD19- relapse primarily arises through three mechanisms. First, pre-existing CD19- subclones, particularly those with progenitor-like features, expand because of their survival advantages. Second, CD19 expression is downregulated through pre-existing or newly acquired genetic alterations (mutations and abnormal splicing), epigenetic silencing, and post-transcriptional dysregulation. Third, lineage switching to a myeloid phenotype increases notably after CAR-T cell treatment. This myeloid conversion is frequently associated with KMT2A rearrangements and is driven by epigenetic reprogramming, impaired expression of B-cell regulators, and the presence of bipotent progenitors within leukemia or lymphoma. CD19- relapse constitutes a major clinical barrier to the durable efficacy of CD19-CAR T-cell therapy. Understanding these diverse escape mechanisms is crucial for developing preventive strategies and effective salvage therapies to maintain long-term remission. To mitigate CD19- relapse, a coordinated dual strategy is needed. First, novel therapeutic approaches should be developed, including CAR products targeting alternative antigens, optimized salvage regimens, and CD19 re-induction strategies. Second, high-resolution molecular profiling should be used to identify high-risk patients and guide pre-emptive or combinatorial interventions based on the molecular underpinnings of CD19- relapse. Together, these approaches will deepen mechanistic insight into CD19- relapse and enable targeted prevention and management of this key limitation of CAR T-cell therapy.

Для цитирования: Huang Jiawen, Huang Xiaobing, Yu Duonan. CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1692287.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.